Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from SAB Biotherapeutics (SABS).
SAB Biotherapeutics has successfully completed the third cohort dosing in phase one trials for their new drug, SAB-142, without any cases of serum sickness reported. The company plans to release a detailed corporate update mid-April, which could be a significant point of interest for investors and followers of the biotech industry.
For an in-depth examination of SABS stock, go to TipRanks’ Stock Analysis page.
